A5004272744- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Treatment and Research
- Neuroendocrine Tumor Research Advances
- Medical Imaging Techniques and Applications
- Lung Cancer Research Studies
- Prostate Cancer Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Neuroblastoma Research and Treatments
- Medical Imaging and Pathology Studies
- Thyroid Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Pancreatic and Hepatic Oncology Research
- Meningioma and schwannoma management
- Mass Spectrometry Techniques and Applications
- Advanced Radiotherapy Techniques
- Peptidase Inhibition and Analysis
- Cardiac Imaging and Diagnostics
- Thyroid and Parathyroid Surgery
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Bone health and treatments
- Urologic and reproductive health conditions
- Glioma Diagnosis and Treatment
Ludwig-Maximilians-Universität München
2016-2025
LMU Klinikum
2016-2025
Ihre-Radiologen
2022-2025
Klinik und Poliklinik für Nuklearmedizin
2018-2023
Klinik und Poliklinik für Strahlentherapie und Radioonkologie
2021-2023
European Neuroendocrine Tumor Society
2019-2023
München Klinik
2019-2022
University Hospital Ulm
2019-2021
German Cancer Research Center
2019
University Hospital Heidelberg
2019
In retrospective studies, 68Ga-PSMA-11 positron emission tomographic (PET) imaging improves detection of biochemically recurrent prostate cancer compared with conventional imaging.To assess PET accuracy in a prospective multicenter trial.In this single-arm trial conducted at University California, San Francisco and Los Angeles, 635 patients after prostatectomy (n = 262, 41%), radiation therapy 169, 27%), or both 204, 32%) underwent PET. Presence was recorded by 3 blinded readers on...
Abstract Purpose: Systemic androgen-signaling inhibition added to ongoing androgen-deprivation therapy (ADT) improved clinical outcomes in patients with nonmetastatic castration-resistant prostate cancer without detectable metastases by conventional imaging (nmCRPC). Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) detects superior sensitivity imaging, but its performance nmCRPC remains largely unknown. We characterized burden high-risk using PSMA-PET....
// Wolfgang P. Fendler 1,2 , Svenja Reinhardt 1 Harun Ilhan Andreas Delker Guido Böning Franz J. Gildehaus Christian Stief 3,4 Peter Bartenstein 1,4 Gratzke Sebastian Lehner and Axel Rominger Department of Nuclear Medicine, Ludwig-Maximilians-University Munich, Germany 2 Molecular Medical Pharmacology, David Geffen School Medicine at UCLA, Los Angeles, CA, USA 3 Urology, 4 Comprehensive Cancer Center, Correspondence to: Fendler, email: Keywords : mCRPC; PET; prostate cancer; PSMA;...
Treatment of advanced metastatic castration-resistant prostate cancer after failure approved therapy options remains challenging. Prostate-specific membrane antigen (PSMA)–targeting β- and α-emitters have been introduced, with promising response rates. Here, we present the first—to our knowledge—clinical data for PSMA-targeted α-therapy (TAT) using <sup>225</sup>Ac-PSMA imaging (I&T). <b>Methods:</b> Fourteen patients receiving <sup>225</sup>Ac-PSMA-I&T were included in this...
The prognosis of patients with progressive meningioma after failure surgery and radiotherapy is poor. We retrospectively evaluated the safety efficacy somatostatin-receptor (SSTR)-targeted radionuclide therapy (177Lu-DOTATATE [n = 16], 90Y-DOTATOC 3], or both 1]) in progressive, treatment-refractory meningiomas (5 World Health Organization [WHO] grade I, 7 WHO II, 8 III) part multifocal disease (17 20 patients). SSTR treatment (median 3 cycles, median administered dose/cycle 7400 MBq) led to...
Abstract Introduction The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) receiving [ 177 Lu]Lu-PSMA-617 therapy has been the subject controversy. Therefore, WARMTH decided to plan a multicenter retrospective analysis (the “617 trial”) evaluate response rate and OS as well therapies more than 300 treated Lu-PSMA-617. Materials methods data 631 metastatic CRPC (mCRPC) from 11 different clinics were...
(90)Y radioembolization (selective internal radiation therapy [SIRT]) is a valuable therapeutic option for unresectable hepatic metastases arising from primary colorectal cancer. The present study evaluated the prognostic value of (18)F-FDG PET/CT metabolic parameters predicting survival after SIRT.Eighty patients with cancer were treated SIRT. was performed at baseline and 3 mo treatment. Metabolic volume, total lesion glycolysis, maximum peak standardized uptake (SUV(max) SUV(peak),...
This study analyzed the predictive value of <sup>99m</sup>Tc-labeled macroaggregated albumin (<sup>99m</sup>Tc-MAA) SPECT for <sup>90</sup>Y-labeled resin microsphere therapy (radioembolization) by comparing uptake on pretherapeutic <sup>99m</sup>Tc-MAA with posttherapeutic <sup>90</sup>Y-bremsstrahlung SPECT. <b>Methods:</b> We included 502 patients (55% male; mean age ± SD, 62 11 y) who underwent radioembolization between 2005 and 2013 because primary or secondary liver malignancies...
Early identification of aggressive disease could improve decision support in pancreatic neuroendocrine tumor (pNET) patients prior to peptide receptor radionuclide therapy (PRRT). The prognostic value intratumoral textural features (TF) determined by baseline somatostatin (SSTR)-positron emission tomography (PET) before PRRT was analyzed. Thirty-one with G1/G2 pNET were enrolled (G2, n = 23/31). Prior [177Lu]DOTATATE (mean, 3.6 cycles), SSTR-PET computed performed. By segmentation 162...
NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastasized NET. The present study evaluates the outcome further PRRT so called salvage setting after initial response to therapy later progression.Thirty five (pat.) (25 male, 10 female, 63 ± 9 years) progressive, NET (23 small intestinal, 5 lung, 4 CUP, 1 rectal, gastric paraganglioma) were included. All previously received 177Lu-DOTATATE showed response....
Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) detects prostate cancer recurrence at low PSA levels. Radiotherapy with dose escalation to the former bed has been associated improved biochemical recurrence-free survival (BRFS). Thus, we hypothesized that PSMA PET/CT-guided salvage radiotherapy leads BRFS. Methods: A total of 204 consecutive patients were referred for following radical prostatectomy. PET/CT scans performed and persistence (109...
// Rudolf A. Werner 1,* , Constantin Lapa Harun Ilhan 2 Takahiro Higuchi 1 Andreas K. Buck Sebastian Lehner Peter Bartenstein Frank Bengel 3 Imke Schatka 4 Dirk O. Muegge 5 László Papp 6 Norbert Zsótér 7 Tobias Große-Ophoff 8 Markus Essler and Ralph Bundschuh Department of Nuclear Medicine, University Hospital Würzburg, Germany Ludwig-Maximilians-University Munich, Hannover Medical School, Hannover, Charité - Universitätsmedizin Berlin,...
PSMA PET/CT visualises prostate cancer residual disease or recurrence at lower PSA levels compared to conventional imaging and results in a change of treatment remarkable high number patients. Radiotherapy with dose escalation the former bed has been associated improved biochemical recurrence-free survival. Thus, it can be hypothesised that PET/CT-based radiotherapy might improve prognosis these One hundred twenty-nine patients underwent due persistence (52%) (48%) after radical...
<sup>68</sup>Ga-prostate-specific membrane antigen PET/CT (<sup>68</sup>Ga-PSMA PET/CT) offers unprecedented accuracy for staging of primary, persistent, or recurrent prostate cancer. Thus, we hypothesized that <sup>68</sup>Ga-PSMA before radiotherapy significantly affects the radiotherapeutic approach in comparison to current standard, a CT-based approach. <b>Methods:</b> Between February 2014 and December 2017, 172 patients underwent were included this retrospective analysis. Twenty-two...
Readers need to be informed about potential pitfalls of [68Ga]Ga-PSMA-11 PET interpretation.Here we report findings discordant with the histopathology/composite reference standard in a recently published prospective trial on 635 patients biochemically recurrent prostate cancer.Consensus reads were false positive 20 regions 17/217 (8%) lesion validation. Majority interpretations (13 20, 65%) occurred context suspected (bed) relapse (T) after radiotherapy (n = 11); other noted for bed post...
With the increased use of focal radiation dose escalation for primary prostate cancer (PCa), accurate delineation gross tumor volume (GTV) in prostate-specific membrane antigen PET (PSMA-PET) becomes crucial. Manual approaches are time-consuming and observer dependent. The purpose this study was to create a deep learning model intraprostatic GTV PSMA-PET.
Previously, we demonstrated that prostate-specific membrane antigen positron emission tomography (PSMA-PET) revealed distant metastases in 109/200 patients (39% nodes, 24% bone, and 6% visceral organ) with nonmetastatic castration-resistant prostate cancer (nmCRPC) high-risk features (International Society of Urological Pathology score ≥4 and/or doubling time ≤10 mo) without by conventional imaging. However, the impact disease extent determined PSMA-PET on patient outcomes is unknown. We...